Reporting on results gathered from its antibody and assay kit departments, AnaSpec has released data that supports the efficacy of its MOG(35-55) peptide. Analytical results reported the following: AnaSpec’s mouse/rat MOG(35-55) peptide induced EAE in C57BL/6 mice with 100% incident (10/10).... - July 28, 2007 - AnaSpec, Inc.

AnaSpec has introduced acetylated, mono-methylated, di-methylated and tri-methylated Lysine for the synthesis of histone peptides. The use of these building blocks, although not limited to making synthetic histone peptides, provides additional tools for researchers to help unravel the “histone... - July 28, 2007 - AnaSpec, Inc.

On July 25, 2007 Synergy Research Group (SynRG), a Russia-based CRO, presented the current issue of its Orange Paper, a regular analytical report on the market of clinical trials in Russia. The report contains hundreds of figures as well as 11 Tables and 9 Pictures covering various aspects of the Russian... - July 27, 2007 - Synergy Research Group

Today AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced fourteen (14) new peptides for drug discovery research. HIV Nef (68–76) - Cat# 61673 This HIV nef peptide 68 to 76 amino acids was identified in HIV-infected individuals. It is a B7 restricted... - July 27, 2007 - AnaSpec, Inc.

Continuing in its commitment to rapidly expand its antibody offerings, AnaSpec, a leading provider of integrated proteomics solutions, added twelve (12) new antibodies to its growing collection of catalog antibodies. The targeted research area for these antibodies is signal transduction and matrix metalloproteinases. Anti-DEFCAP... - July 26, 2007 - AnaSpec, Inc.

Today AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced ten (10) new peptides for drug discovery research. MUC4 - Cat# 61339 This peptide is derived from the tandem repeat of Muc 4 mucin protein. Mucins are highly O-glycosylated proteins which polymerize... - July 25, 2007 - AnaSpec, Inc.

The Tampa-based contract research organization acquires a brand new building. - July 23, 2007 - Xcelience, LLC

This week AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced eleven (11) new peptides for drug discovery research. - July 22, 2007 - AnaSpec, Inc.

Cathelicidins are cationic peptides that have broad-range antimicrobial activity. These peptides belong to the family of anti-microbial peptides which form part of the host’s important innate immunity mechanism. - July 20, 2007 - AnaSpec, Inc.

AnaSpec has introduced its newest antibody solutions – anti-MMP-1 (Hinge) and anti-MMP-13 (Hinge) antibodies. Strategically raised against the hinge regions of MMP-1 and MMP-13, the epitopes do not overlap the catalytic domain and will not influence the activity of the MMP ferment in experiments.... - July 19, 2007 - AnaSpec, Inc.

Gamma Medica-Ideas Inc. (GM-I), a leader in providing next-generation medical imaging devices for the pre-clinical and clinical markets, announced today that Université de Rouen in France has placed an order for a dual-modality Flex TriumphTM pre-clinical platform – including its revolutionary... - July 19, 2007 - Gamma Medica-Ideas

The “Premix vs. Custom TPN” technical paper, sponsored by Baxa Corporation, is now available at Expert411.com for media and professional access. The paper, which provides a history of nutritional best practice and an examination of the use of premixed solutions for parenteral nutrition, is authored by Louis S. Diorio, RPh, and David L. Thomas, RPh MBA, both with Certified Consultant Pharmacists Healthcare Associates , Inc of Chatham, NJ. - July 18, 2007 - Baxa Corporation - Featured Press Release

For the second year in a row, Englewood-based Baxa Corporation has been selected as one of Colorado’s best companies to work for; based on results from employee surveys by the Society for Human Resource Management (SHRM). Best Company finalists promote the best employment opportunities in the state – attracting new workers and promoting their retention. - July 16, 2007 - Baxa Corporation - Featured Press Release

At the 2007 annual conference of the American Peptide Society, AnaSpec presented a technical poster that described the facile synthesis of a hydrocarbon-stapled peptide. Asymmetric synthesis of (S)-Fmoc-α-(2’-pentenyl)-alanine was successfully accomplished via an Ala-Ni (II)-BPB-complex [3]... - July 14, 2007 - AnaSpec, Inc.

At the 2007 annual conference of the American Peptide Society, AnaSpec presented a “late-breaking” technical poster that described in vivo imaging using a tissue-specific near infrared fluorescent peptide conjugate. Extracellular matrix proteins that contain the Arg-Gly-Asp (RGD) sequence,... - July 13, 2007 - AnaSpec, Inc.

Cornerstone BioPharma™, the Triangle-based specialty pharmaceutical company currently focused on the development and commercialization of niche prescription medications in the respiratory arena, today announced it has signed a co-promotion agreement with SJ Pharmaceuticals (SJP). This agreement... - July 12, 2007 - Cornerstone BioPharma

Magellan BioScience Group, Inc. (Magellan), a pioneer in innovative drug discovery and development from marine microbial sources, and the University of South Florida (USF) announced today that they have been awarded a Phase I Small Business Innovative Research Grant (SBIR) from the National Institute... - July 06, 2007 - Magellan BioScience Group, Inc.

Baxa Corporation is promoting its industry-leading STAR Center pharmacy training facility, CriticalPoint™ online sterile compounding certification training, Abacus TPN ordering and calculation software and the ValiMed System for medication validation at the American Society of Health-System Pharmacists 2007 Summer Meeting and Exhibition beginning today at the Moscone Center in San Francisco. - June 25, 2007 - Baxa Corporation - Featured Press Release

The June issue of PharmaChem, an Italian journal covering the drug discovery industry, featured an article written by AnaSpec called “Peptides as Antigens.” The technical article, written by Dr. Daniel Li and Cecilia Po, outlines the advantages and methodologies behind using peptides as antigens. Company... - June 24, 2007 - AnaSpec, Inc.

Leveraging one of the world’s largest collections of amyloid peptides, AnaSpec has introduced its latest development in novel solutions for amyloid-related research - the new SensoLyte™ 520 Beta-Secretase Assay Kit. Beta-secretase catalyzes a key step in the production of beta-amyloid peptides... - June 22, 2007 - AnaSpec, Inc.

Gamma Medica-Ideas Inc. (GM-I), a leader in providing next-generation medical imaging devices for the pre-clinical and clinical markets, announced today the sale of a dual-headed LumaGEM® system for applications such as Molecular Breast Imaging (MBI). This dual head system is the first of its kind. Gamma... - June 22, 2007 - Gamma Medica-Ideas

Bio-Synthesis joined with Protein Lounge to bring all the vital and necessary databases to one place. Users have access to the Protein Database, Peptide Antigen Database, and the siRNA database. - June 21, 2007 - Bio-Synthesis Inc. - Premium Press Release

Baxa Corporation and Health Robotics announce a strategic alliance to use the Baxa Two-Fer™ Needles with Health Robotics’ CytoCare™ Robot in order to safely and accurately automate the preparation of patient-specific chemotherapy IV admixtures. This alliance combines state-of-the-art technologies to achieve the accuracy and sterility that providers require. The resulting technology is the only totally automated system for handling hazardous IV admixtures available in the market. - June 18, 2007 - Baxa Corporation - Featured Press Release

A team of researchers at University of Kuopio’s A.I Virtanen Institute for Molecular Sciences in Finland is conducting studies in non-invasive imaging with Gamma Medica-Ideas’ MicroSPECT/CT system to provide essential information on biodistribution of gene therapy vectors in rats. The A.I.... - June 17, 2007 - Gamma Medica-Ideas

Gamma Medica-Ideas (GM-I) announced today the addition of a new High Resolution CT subsystem to the company’s FLEX Triumph™ Pre-clinical Imaging Platform that produces striking improvements in CT imaging. The new CT subsystem contains a variable focal spot x-ray source which provides the... - June 17, 2007 - Gamma Medica-Ideas

Thrombotargets Corporation and Magellan Bioscience Group, Inc. today announced the formation of drug discovery joint venture. Under the terms of this agreement, Magellan Bioscience Group, Inc. will provide to Thrombotargets its compounds and extracts from fermentation broths of marine-isolated microorganisms... - June 16, 2007 - Magellan BioScience Group, Inc.

Drawing on its broad portfolio of MOG (35-55) and other multiple sclerosis (MS) experimental autoimmune encephalomyelitis (EAE)-related peptides, AnaSpec has just released its new line of SensoLyte™ Anti - MOG ELISA Kits - the industry’s first and only anti-MOG ELISA kits. Myelin oligodendrocyte... - June 16, 2007 - AnaSpec, Inc.

The ValiMed Medication Validation System and related information are now available at PublicRelationsNewsroom.com. The ValiMed System, distributed by Baxa Corporation, offers clinicians a simple and cost-effective tool to ensure medication safety by verifying that medications are correctly compounded. Its patented technology validates compounded doses of high risk medications prior to dispensing. - June 15, 2007 - Baxa Corporation - Featured Press Release

Baxa Corporation is profiled as one of eight world-class quality and regulatory teams in the June 2007 issue of Medical Device & Diagnostic Industry magazine. The June article was the first time MD&DI recognized the accomplishments of the quality and regulatory teams that ensure medical products are safe and ready for market. - June 13, 2007 - Baxa Corporation - Featured Press Release

At the 2007 Experimental Biology conference in Washington, DC, AnaSpec prepared a technical poster entitled, "A Sensitive Fluorimetric Assay for Detection of beta-Secretase Activity Using a Novel FRET Peptide Substrate." The poster documented the following findings: • A highly sensitive... - June 08, 2007 - AnaSpec, Inc.

According to Synergy Research Group, a Russia-based CRO, the growth in the number of clinical trials approved by the Russian Federal Agency for Health Care and Social Development (Roszdravnadzor) made up to nearly 40% in the 1st Quarter of 2007 as compared to the same quarter of the previous year. At the same time, the share of clinical studies initiated by Russian manufacturers has increased. - June 06, 2007 - Synergy Research Group

Functional Genetics, Inc. Announces a New Award from the National Institute of Allergy and Infectious Diseases to Utilize Its Core Random Homozygous Gene Perturbation and Host-Oriented Therapeutics Technologies to Identify and Validate New Therapeutic Approaches to Combat HIV Infection - June 03, 2007 - Functional Genetics, Inc.

Bio-Synthesis has released an updated description for peptide synthesis; this allows peptide researchers to get a view of the broad spectrum of our capabilities: Peptides are complex molecules and each peptide sequence is unique with regard to its chemical and physical properties. Peptides are synthesized... - June 01, 2007 - Bio-Synthesis Inc. - Premium Press Release

The antithrombotics market with the two blockbusters enoxaparin and prasugrel is challenged by generic products as well as by next generation anticoagulants with oral administration and antithrombotics with an improved risk-benefit ratio - June 01, 2007 - La Merie Business Intelligence

Bioactivation of drug candidates resulting in chemically reactive, electrophilic metabolites have always presented a major challenge to pharmaceutical companies. Moreover, the measurement of these metabolites has been hampered by the lack of an effective quantitative method. QA-GSH is a novel new tool... - May 31, 2007 - AnaSpec, Inc.

Colorado Governor Bill Ritter signed House Bill 1060 into law Wednesday afternoon, with the bill sponsors present to acknowledge the importance of the legislation to the bioscience industry in Colorado. Rep. Jim Riesberg (D-Weld) and Sen. Brandon Shaffer (D-Longmont) were thanked for their efforts by... - May 25, 2007 - Colorado BioScience Association - Featured Press Release

The Tampa-based Contract Research Organization signed a partnership that will form new opportunities in the pharmaceutical industry. - May 24, 2007 - Xcelience, LLC

The insulin receptor is a transmembrane receptor that belongs to the tyrosine kinase receptors class. It is a heterotetrameric glycoprotein composed of disulfide-linked subunits in a β-α-α-β configuration. This transmembrane receptor consists of 95kDa β-subunit, a single transmembrane... - May 23, 2007 - AnaSpec, Inc.

Baxa Ltd, subsidiary of Denver-based Baxa Corporation, has moved to a direct sales and marketing model for the Swiss market. The company provides systems and devices for simplifying the handling, mixing and administration of fluid medications. Direct operations will provide Baxa Ltd with improved customer access for product development and continuous improvement, while continuing their excellent customer service. - May 21, 2007 - Baxa Corporation - Featured Press Release

Jack Wheeler, CEO of MicroPhage, Inc., Longmont, is the new chairperson of the board of directors for the Colorado BioScience Association (CBSA). He was appointed at the association’s 2007 annual meeting April 24th. Wheeler assumes chairperson responsibilities from Ed Wood, ArcScan, Inc. In other action, eight new board members were appointed to three-year terms. - May 18, 2007 - Colorado BioScience Association - Featured Press Release

While West Nile virus (WNV) has had significant outbreaks throughout the world since it was first identified, commercially available assay kits for the detection of WNV protease inhibitors had not been developed until now. With the SensoLyte™ series of WNV Protease Assay Kits AnaSpec, a worldwide... - May 17, 2007 - AnaSpec, Inc.

Baxa Corporation's direct marketing campaign for the Rapid-Fill™ Automated Syringe Filler was awarded a Business Marketing Association Gold Key in the Colorado Chapter’s 2007 competition. Three messages: Safety is Automatic, Technology that Fits and Designed for Speed emphasized the key attributes that differentiate the Baxa product from competitive products and processes. - May 16, 2007 - Baxa Corporation - Featured Press Release

On April 25, 2007, the first issue of the Orange Paper – the first analytical review on market of clinical trials in Russia – was officially presented. The strategic goals of Synergy Research Group, a Russia-based emerging CRO, are formation of a civilized market of clinical trials in Russia,... - May 16, 2007 - Synergy Research Group

Those seeking improved sleep can switch on Sleep on Command™ device designed to enforce Delta rhythm sleep and the recovery that best occurs during deep, slow-wave, Delta-stage sleep. - May 08, 2007 - EarthPulse Technologies, LLC

Baxa Corporation announces its agreement with CriticalPoint LLC to co-market a Web-based sterile compounding curriculum authored by internationally recognized subject matter experts. This comprehensive, ACPE-approved program consists of 32 modules that meet USP Chapter 797’s competency assessment requirements. Modules are self-paced and part of CriticalPoint’s Learning Management System (LMS), offering access from any Web connection and providing administrative reporting for tracking. - May 07, 2007 - Baxa Corporation - Featured Press Release

Colorado Bioscience Association is releasing the new edition of Bioscience Colorado Magazine at the 2007 BIO International Convention, May 6-9, at the Boston Convention & Exhibition Center. This year’s magazine has expanded to 80 pages and includes an updated directory of the Colorado Bioscience industry: Medical Device and Related Companies; Biotechnology, Pharmaceutical and Related Companies; Biofuels and Related Companies; Research & Education Institutions; Foundations; & Service Providers. - May 06, 2007 - Colorado BioScience Association - Featured Press Release

“Premature Infants Safer Because Of New Feeding System,” a case study from Premier, Inc., and its member hospitals, in collaboration with Baxa Corporation and VIASYS MedSystems, is now accessible at PublicRelationsNewsroom.com. According to the case, thanks to the collaboration, tiny infants receiving nutrition through feeding tubes now face far less danger from the risk of IV lines and feeding tubes being accidentally connected. - May 03, 2007 - Baxa Corporation - Featured Press Release

Farmers were able to reduce their costs of production, while more effectively controlling pests and better protecting themselves and their farms – all thanks to a practical training programme with farmers in rural China. “Responsible use of crop protection products increases food productivity... - May 01, 2007 - CropLife Asia

Baxa Corporation announces its new syringes, designed for enteral feeding only, have been accepted on contract with key group purchasing organizations to facilitate hospital compliance with patient safety goals and to prevent wrong-route errors. Contracts for enteral syringes have been made between Baxa and these top US group purchasing organizations: AmeriNet, MedAssets, Novation and Premier. - April 30, 2007 - Baxa Corporation - Featured Press Release

The LAMBDA MINIFOR fermenter / bioreactor provides a new heating system for precise, fast and economic heating of the culture medium in fermentation and cell culture processes - April 29, 2007 - LAMBDA Laboratory Instruments